738 related articles for article (PubMed ID: 24012452)
1. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients.
Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K
Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452
[TBL] [Abstract][Full Text] [Related]
2. Non-small cell carcinoma: comparison of postoperative intra- and extrathoracic recurrence assessment capability of qualitatively and/or quantitatively assessed FDG-PET/CT and standard radiological examinations.
Onishi Y; Ohno Y; Koyama H; Nogami M; Takenaka D; Matsumoto K; Yoshikawa T; Matsumoto S; Maniwa Y; Nishimura Y; Sugimura K
Eur J Radiol; 2011 Sep; 79(3):473-9. PubMed ID: 20547021
[TBL] [Abstract][Full Text] [Related]
3. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
[TBL] [Abstract][Full Text] [Related]
4. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of different imaging modalities in the assessment of distant metastasis and local recurrence of tumor in patients with non-small cell lung cancer.
Ohno Y; Yoshikawa T; Kishida Y; Seki S; Koyama H; Yui M; Kassai Y; Aoyagi K; Kaminaga S; Sugimura K
J Magn Reson Imaging; 2017 Dec; 46(6):1707-1717. PubMed ID: 28419645
[TBL] [Abstract][Full Text] [Related]
6. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
[TBL] [Abstract][Full Text] [Related]
8. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients.
Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K
Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045
[TBL] [Abstract][Full Text] [Related]
10. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients.
Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K
Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709
[TBL] [Abstract][Full Text] [Related]
11. Role of combined DWIBS/3D-CE-T1w whole-body MRI in tumor staging: Comparison with PET-CT.
Manenti G; Cicciò C; Squillaci E; Strigari L; Calabria F; Danieli R; Schillaci O; Simonetti G
Eur J Radiol; 2012 Aug; 81(8):1917-25. PubMed ID: 21908120
[TBL] [Abstract][Full Text] [Related]
12. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous positron emission tomography/magnetic resonance imaging for whole-body staging in patients with recurrent gynecological malignancies of the pelvis: a comparison to whole-body magnetic resonance imaging alone.
Grueneisen J; Beiderwellen K; Heusch P; Gratz M; Schulze-Hagen A; Heubner M; Kinner S; Forsting M; Lauenstein T; Ruhlmann V; Umutlu L
Invest Radiol; 2014 Dec; 49(12):808-15. PubMed ID: 25010207
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT.
Ng SH; Chan SC; Yen TC; Liao CT; Chang JT; Ko SF; Wang HM; Lin CY; Chang KP; Lin YC
Eur Radiol; 2010 Sep; 20(9):2229-40. PubMed ID: 20393714
[TBL] [Abstract][Full Text] [Related]
16. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.
Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA
Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917
[TBL] [Abstract][Full Text] [Related]
17. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.
Schmidt GP; Baur-Melnyk A; Herzog P; Schmid R; Tiling R; Schmidt M; Reiser MF; Schoenberg SO
Invest Radiol; 2005 Dec; 40(12):743-53. PubMed ID: 16304476
[TBL] [Abstract][Full Text] [Related]
18. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients.
Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Kotani Y; Nishimura Y; Higashino T; Sugimura K
J Magn Reson Imaging; 2007 Sep; 26(3):498-509. PubMed ID: 17729341
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy.
Schmidt GP; Paprottka P; Jakobs TF; Hoffmann RT; Baur-Melnyk A; Haug A; Notohamiprodjo M; Baur-Melnyk A; Nikolaou K; Reiser MF; Rist C
Eur J Radiol; 2012 Mar; 81(3):e269-76. PubMed ID: 21398060
[TBL] [Abstract][Full Text] [Related]
20. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial.
Yi CA; Lee KS; Lee HY; Kim S; Kwon OJ; Kim H; Choi JY; Kim BT; Hwang HS; Shim YM
Cancer; 2013 May; 119(10):1784-91. PubMed ID: 23423920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
